Skip to main content

Table 3 Comparison of outcome between IS and non-IS groups in patients with lung cancers undergoing surgical resection via VATs and thoracotomy

From: Is incentive spirometry beneficial for patients with lung cancer receiving video-assisted thoracic surgery?

 

VATS

  

Thoracotomy

 

IS

Non-IS

IS vs. Non-IS

IS

Non-IS

IS vs. Non-IS

Outcome

Mean

SD

Median

Mean

SD

Median

Estimate

(95% CI)

Mean

SD

Median

Mean

SD

Median

Estimate

(95% CI)

Hospitalization cost (USD)1

5976.8

3823

5295.5

6568.4

4994.5

5536.5

−524.5

(−982.6, −66.4)*

5668.3

4851.4

4864.6

6425.9

7440.6

4904.6

− 705.5

(− 1013, − 398.3)***

Length of stay (d)1

19.3

80.9

13

18.3

40.1

13

1.13

(−5.72, 7.97)

19.5

20.4

16

23.3

117.6

17

−3.60

(−7.27, 0.07)

Pneumonia (n, %)2

23

3.09

 

36

5.46

 

0.55

(0.32, 0.95)*

234

5.56

 

120

6.19

 

0.90

(0.72, 1.14)

ADRS (n, %)2

0

0.00

 

2

0.30

 

NA

 

3

0.07

 

2

0.10

 

0.82

(0.14, 4.97)

3-month outcome

 ED visit frequency1

0.27

0.69

0

0.28

0.93

0

−0.02

(−0.10, 0.07)

0.30

0.78

0

0.31

0.85

0

−0.02

(−0.06, 0.03)

 Hospitalization frequency1

0.59

1.06

0

0.63

1.08

0

−0.05

(−0.16, 0.05)

0.54

1.01

0

0.50

0.98

0

0.02

(−0.03, 0.07)

6-month outcome

 ED visit frequency1

0.48

1.02

0

0.51

1.31

0

− 0.03

(− 0.15, 0.09)

0.54

1.22

0

0.55

1.23

0

−0.01

(− 0.08, 0.05)

 Hospitalization frequency1

1.20

1.89

0

1.24

2.01

0

−0.07

(− 0.26, 0.11)

1.16

1.91

0

1.05

1.74

0

0.08

(−0.02, 0.18)

1-year outcome

 ED visit frequency1

0.79

1.50

0

0.94

2.24

0

−0.17

(−0.36, 0.03)

0.98

1.99

0

0.93

1.66

0

0.04

(−0.06, 0.14)

 Hospitalization frequency1

1.81

2.72

0

1.83

2.80

0

−0.08

(−0.34, 0.18)

1.87

2.77

0

1.74

2.64

0

0.07

(−0.07, 0.21)

  1. 1 USD = 31.54 NTD in 2008; IS: incentive spirometry;
  2. 1Linear regression after adjusted for age, gender, COPD, asthma, other cancer, heart failure, neoadjuvant and procedure method
  3. 2Logistic regression after adjusted for age, gender, COPD, asthma, other cancer, heart failure, neoadjuvant and procedure method
  4. * p < 0.05, ** p < 0.01, *** p < 0.001